Volume 10, Issue 11, November 2024,
Publish Date: 13-11-2024
Doi https://doi.org/10.55640/ijmsdh-10-11-05

International Journal of Medical Science and Dental Health (Open Access)

MOLECULAR INSIGHTS INTO THE REPLICATION AND PATHOGENESIS OF HEPATITIS C VIRUS

ALI HASSANEN ALI[1]

[1]*National Center of Hematology, Mustansiriyah University, Baghdad, Iraq.*

ABSTRACT

Hepatitis C virus (HCV) is a major infectious disease problem worldwide, resulting in serious liver disease, including cirrhosis and hepatocellular carcinoma. This review article acts as a general overview of molecular aspects of HCV replication and pathogenesis emphasizing the virus structure and genome, entry mechanisms, the replication cycle, and HCV interactions with the host immune system. It also examines the progression of disease-causing HCV infections and the clinical symptoms. Antiviral treatments have improved patient outcomes, but they remain far from an effective vaccine, because viral diversity, lack of access to health care, remain. Research in the future should look to increase healthcare accessibility, to understand long term outcomes after treatment, and to develop the vaccine. Solution to these challenges will enable us to diminish the worldwide burden of HCV and better patient health results.

INTRODUCTION

Hepatitis C virus (HCV) is an important global health challenge and estimated to affect 71 million people worldwide, a single stranded RNA virus from the family of Flaviviridae. Primary transmission of most acute and chronic hepatic disease is by exposure of infected blood. Hepatic complications of these diseases include cirrhosis and hepatocellular carcinoma. HCV remains a major public health threat, however, because of the chronic nature of infection and resultant severe liver outcomes despite the availability of highly effective antiviral therapies [1-3].

HCV replication cycle is a multifaceted series of events that includes viral entry, genomic replication, and virion assembly. It is critical for the recognition of potential therapeutic targets to have a detailed understanding of these processes at the molecular level. Molecular biology techniques have recently progressed to the point where critical mechanisms by which HCV exploits host cellular pathways for its replication have been illuminated. Additionally, several HCV strategies to avoid host immune surveillance have been investigated to contribute to the persistence of infection [4, 5].

Studies of the immune system host interactions with HCV are needed to delineate the pathogenesis of HCV associated liver diseases. The virus can also allow chronic infection, and has the capacity to modulate host immune responses to influence progression of liver pathology. In this review, we attempt to provide a comprehensive synthesis of recent knowledge of HCV replication and pathogenesis on the

basis of recent investigative efforts at the molecular level. Making this knowledge integrable will allow us to draw attention to critical research gaps and propose how further research directions can enhance therapeutic approaches to HCV.

Hepatitis C Virus Genome and Structure

Hepatitis C virus (HCV) is an enveloped positive sense, single stranded RNA virus of 9.6 kilobases. But infectivity and replication require that the viral particle contain structural components.

Structure of the Virus [6-9]

1. **Envelope Proteins:** HCV has two major glycoproteins E1 and E2 embedded in a lipid bilayer prepared from the host cell membrane, which surrounds HCV. Viral entry into host cells requires the attachment and fusion of viral envelope proteins with the host cell membrane. The immune evasion also results from the high variability of E1 and E2 proteins.
2. **Nucleocapsid:** The viral RNA genome is wrapped in the nucleocapsid, where the core protein encases it, inside the envelope. In addition to structural stability, the core protein has roles in RNA packaging and virus assembly.

Genomic Organization [10-13]

The HCV genome is a single ORF flanked by well characterized highly structured, untranslated regions (UTRs) at the 5' and 3' ends. These UTRs are needed for virus replication and translation.

1. **5' Untranslated Region (UTR):** It contains an internal ribosome entry site (IRES) which facilitates cap-independent translation of the viral RNA, and thus allows efficient synthesis of viral proteins in the host cell cytoplasm.
2. **Open Reading Frame (ORF):** The ORF encodes a large polyprotein precursor of approximately 3000 amino acids, which is co and post translational processed by host and viral proteases to produce ten mature proteins. These include:

- Structural Proteins: Core, E1, and E2.
- Non-Structural Proteins: NS2, NS3, NS4A, NS4B, NS5A and NS5B. However, these proteins are involved in viral replication, assembly and modulation of host cell pathways [14, 15].

3. **3' Untranslated Region (UTR):** It has a role in genome replication and stability in this region. Sequences required for initiation of RNA synthesis by the viral RNA dependent RNA polymerase (NS5B) are present [16].

Genetic diversity of HCV is noteworthy; it includes at least seven major genotypes and many subtypes. The genetic variability has an effect on disease progression, treatment response and vaccine development [17].

Table 1 *(Structure and Genomic Organization of Hepatitis C Virus.)*

Component	Description	Function

Envelope Proteins (E1, E2)	Embedded in the lipid bilayer derived from the host cell membrane. Composed of glycoproteins with high variability.	Facilitate viral entry by mediating attachment and fusion with host cells. Contribute to immune evasion.
Nucleocapsid	Formed by the core protein encapsulating the viral RNA genome. Located beneath the lipid envelope.	Provides structural stability, RNA packaging, and is essential for virus assembly.
5' Untranslated Region (UTR)	Contains an internal ribosome entry site (IRES) that allows ribosomes to bind directly to viral RNA.	Enables cap-independent translation of viral RNA, critical for protein synthesis in host cells.
Open Reading Frame (ORF)	Encodes a polyprotein precursor of approximately 3,000 amino acids, processed into ten mature proteins by host and viral proteases.	Structural proteins (Core, E1, E2) and non-structural proteins (NS2, NS3, NS4A, NS4B, NS5A, NS5B) involved in replication and assembly.
3' Untranslated Region (UTR)	Contains structured elements necessary for the initiation of RNA synthesis by the viral RNA-dependent RNA polymerase (NS5B).	Plays a role in genome replication, stability, and regulation of viral RNA synthesis.

Viral Entry Mechanism [18, 19]

1. **Attachment:** Attachment of the virus to the host cell surface is the first step in the HCV infection. This is mediated by interactions between the viral envelope glycoproteins (E1 and E2) and specific receptors on the surface of hepatocytes, the principal target cells for HCV.
2. **Receptor Binding:** The entry of HCV is mediated by several host cell receptors including:

- **CD81:** A tetraspanin protein that binds directly to the E2 glycoprotein.
- **Scavenger Receptor Class B Type I (SR-BI):** Increases the rate of viral particle binding to the host cell.
- **Claudin-1 and Occludin:** Viral entry post initial attachment facilitated by tight junction proteins.

3. Endocytosis: Once bound to receptor, HCV is internalized into the host cell by clathrin mediated endocytosis. The process of invagination of the cell membrane around the virus receptor complex forms a vesicle to bring the virus into the cell.
4. Fusion and Uncoating: Upon acidification of the endocytic vesicle, conformational changes are induced in the viral envelope proteins, resulting in fusion of the viral envelope with the vesicle membrane. The viral nucleocapsid is released into the cytoplasm of the host cell upon fusion of this viral particle.

Establishment of Infection

1. **Viral RNA Release:** Inside the cytoplasm, the virus disassembles the nucleocapsid and releases the viral RNA genome [20].
2. **Translation and Replication:** The released RNA is immediately translated into a single polyprotein that is then cleaved into functional viral proteins. They are proteins that, located on intracellular membranes, form a replication complex to synthesize new viral RNA genomes [21].
3. **Immune Evasion:** HCV uses multiple mechanisms during initial infection to evade host immune responses including modulation of innate immune signaling pathways and antigen presentation [22].

Table 2 *(Mechanism of Hepatitis C Virus Entry and Initial Infection.)*

Stage	Description	Key Components/Processes
Attachment	Initial binding of the virus to the host cell surface.	Viral glycoproteins E1 and E2; hepatocyte surface receptors
Receptor Binding	Interaction between viral proteins and host cell receptors facilitates entry.	CD81, SR-BI, Claudin-1, Occludin
Endocytosis	Internalization of the virus into the host cell via vesicle formation.	Clathrin-mediated endocytosis
Fusion and Uncoating	Fusion of the viral envelope with the vesicle membrane releases the nucleocapsid into the cytoplasm.	Acidification-triggered conformational changes in viral envelope proteins
Viral RNA Release	Disassembly of the nucleocapsid to release viral RNA into the host cell cytoplasm.	Nucleocapsid disassembly
Translation and Replication	Viral RNA is translated into a polyprotein and processed into functional proteins, initiating RNA replication.	Polyprotein processing; formation of replication complex
Immune Evasion	Strategies employed by HCV to avoid detection and destruction by the host immune system during early infection.	Modulation of innate immune pathways; alteration of antigen presentation

Replication Cycle of Hepatitis C Virus

Hepatitis C virus (HCV) replication cycle is a highly organized process with each of the stages essential for the production of new viral particles. These stages give us a window into the potential therapeutic targets [12].

1. Polyprotein Processing and Translation [4, 23]

- **Initiation:** Once the viral RNA has been released from the cytoplasm, it uses the host's ribosomal machinery to begin translation.
- **Polyprotein Production:** The HCV genome is translated into large polyprotein precursor.
- **Processing:** Host and viral proteases then cleave it to ten mature proteins including structural proteins (Core, E1, E2) and nonstructural proteins (NS2, NS3, NS4A, NS4B, NS5A, NS5B).

2. Replication Complex Formation [24, 25]

- **Membranous Web Formation:** Non-structural proteins stimulate endoplasmic reticulum membrane modifications causing a structure known as membranous web.
- **Replication Complex Assembly:** Replication complex assembly scaffolds are given by the membranous web, in which NS3, NS4A, NS4B, NS5A and NS5B proteins reside.

3. RNA Synthesis [26, 27]

- **Negative Strand Synthesis:** The viral RNA dependent RNA polymerase (NS5B) is responsible for synthesizing a complementary negative strand RNA from the positive strand RNA genome.
- **Positive Strand Synthesis:** As a template for the synthesis of multiple positive strand RNA genomes, the negative strand RNA is encapsulated by the virus.

4. Assembly and Maturation [28, 29]

- **Virion Assembly:** Immutative virions package newly synthesized positive strand RNAs with structural proteins.
- **Lipid Droplet Association:** Instead, the core protein associates with lipid droplets in the host cell and acts to facilitate virion assembly.

Table 3 *(Replication Cycle of Hepatitis C Virus.)*

Stage	Description	Key Components/Processes
Translation and Polyprotein Processing	Viral RNA is translated into a polyprotein, which is cleaved into mature viral proteins.	Host ribosomes, viral and host proteases, structural and non-structural proteins
Formation of the Replication Complex	Non-structural proteins modify the endoplasmic reticulum to form a membranous web for replication.	Membranous web, NS3, NS4A, NS4B, NS5A, NS5B

RNA Synthesis	Synthesis of negative-strand RNA from positive-strand RNA, followed by replication of new positive-strand RNAs.	RNA-dependent RNA polymerase (NS5B), template switching
Assembly and Maturation	Packaging of new RNA genomes with structural proteins into immature virions; association with lipid droplets.	Core protein, lipid droplets, structural proteins
Release	Mature virions acquire a lipid envelope and are released from the cell to infect new cells.	Virion maturation, exocytosis

Molecular Mechanisms of HCV Pathogenesis

The pathogenesis of Hepatitis C virus (HCV) involves complex interactions between the virus and host cellular mechanisms, leading to liver damage and disease progression. These molecular mechanisms are critical for understanding how HCV causes liver pathology and for identifying potential therapeutic targets [30-32].

1. Immune Evasion Strategies

- **Antigenic Variation:** HCV has high genetic variability, especially in the envelope glycoproteins, and can escape neutralizing antibodies.
- **Inhibition of Innate Immunity:** In particular, the virus is capable of subduing the cell's innate immune response, including antagonizing signaling on interferon pathways. Key protein disruption in a cascade of interferon signaling is disrupted by NS3/4A protease.
-

2. Chronic inflammatory and immune modulation

- **Cytokine Production:** Persistent inflammation and liver damage can be driven by the production of pro inflammatory cytokines in chronic HCV infection.
- **T Cell Exhaustion:** Viral persistence is induced by continuous antigen exposure by the virus, which exhausts and paralyzes T cells that are essential for effective immune responses.

3. Direct Cytopathic Effects

- **Cellular Apoptosis:** HCV proteins can directly kill hepatocytes, through apoptosis, and contribute to liver injury.
- **Oxidative Stress:** It causes oxidative stress in liver cells that can damage and cause fibrosis.

4. Liver Fibrosis and Cirrhosis

- **Activation of Stellate Cells:** Hepatic stellate cell activation occurs in the setting of chronic inflammation and oxidative stress and produce extracellular matrix components leading to fibrosis.
- **Fibrogenic Cytokines:** Fibrogenic cytokines, including transforming growth factor beta (TGF-β), are associated with increased levels of fibrosis progression.

5. Hepatocellular Carcinoma (HCC) Development

- **Oncogenic Signaling Pathways:** HCV can disrupt cellular signaling pathways involved in cell proliferation and survival, such as the Wnt/β-catenin and MAPK pathways, and is therefore thought to contribute to oncogenesis.
- **Genomic Instability:** Mutations and genomic instability can result from persistent infection and inflammation leading to HCC.

Table 4 *(Molecular Mechanisms of Hepatitis C Virus Pathogenesis.)*

Mechanism	Description	Key Components/Processes
Immune Evasion Strategies	HCV evades host immune detection and response.	Antigenic variation, inhibition of interferon signaling (NS3/4A protease)
Chronic Inflammation and Immune Modulation	Persistent inflammation and impaired immune response lead to liver damage.	Pro-inflammatory cytokines, T cell exhaustion
Direct Cytopathic Effects	HCV proteins directly cause cellular damage and death.	Induction of apoptosis, oxidative stress
Liver Fibrosis and Cirrhosis	Chronic infection leads to progressive liver scarring and cirrhosis.	Activation of hepatic stellate cells, fibrogenic cytokines (e.g., TGF-β)
Hepatocellular Carcinoma (HCC) Development	Long-term infection contributes to liver cancer development.	Oncogenic signaling pathways (Wnt/β-catenin, MAPK), genomic instability

Host-Virus Interactions in Hepatitis C Virus Infection

HCV interaction with host cellular machinery is critical for viral replication, immune response modulation and pathogenesis. These interactions are complex and multifaceted and affect the outcome of infection [33-35].

1. Viral Replication on Host Cellular Factors

- **Lipid Metabolism:** HCV exploits host lipid metabolism for its replication. It causes lipid droplet formation and exploits these structures as sites for viral assembly.
- **MicroRNA-122:** This liver specific microRNA increases HCV replication by stabilising the viral RNA and facilitating its translation and replication.

2. Host Immune Responses Modulation

- **Interferon Response:** HCV blocks signaling pathways and degrades key signaling proteins to inhibit the host interferon response, a key component of the innate immune system.
- **Cytokine Modulation:** It can also turn cytokine production into a skewed type that is less effective and allows for persistence.

3. Alteration of Host Cell Signaling Pathways.

- **PI3K-Akt Pathway:** PI3K Akt pathway activation is promoted by HCV and may contribute to oncogenesis.
- **MAPK/ERK Pathway:** The virus uses this pathway to promote its replication and influence cell growth, modulating it.

4. Impact on Host Cell Apoptosis and Autophagy.

- **Inhibition of Apoptosis:** In infected cells HCV proteins can inhibit apoptosis and allows prolonged survival of infected cells and the continued replication of the virus.
- **Induction of Autophagy:** The virus may keep itself alive by using autophagy, the process induced by the virus, to get the resources it needs to replicate and to get rid of damaged organelles.

5. Genetic Contribution of Infection Outcome

- **Host Genetics:** For example, DNA variation within a person, such as a 'polymorphism' in a gene called IL28B, affects how susceptible a person is to HCV infection and how well HCV treatment works.
- **HLA Alleles:** Spontaneous viral clearance or chronic infection is associated with certain human leucocyte antigen (HLA) allele.

Table 5 *(Host-Virus Interactions in Hepatitis C Virus Infection.)*

Interaction Type	Description	Key Components/Processes
Host Cellular Factors in Viral Replication	HCV exploits host cell mechanisms to facilitate its replication.	Lipid metabolism, microRNA-122
Modulation of Host Immune Responses	The virus alters host immune responses to evade detection and persist in the host.	Inhibition of interferon response, cytokine modulation

Alteration of Host Cell Signaling Pathways	HCV manipulates cellular signaling to support its life cycle and contribute to disease progression.	PI3K-Akt pathway, MAPK/ERK pathway
Impact on Host Cell Apoptosis and Autophagy	HCV influences cell survival mechanisms to benefit its replication and persistence.	Inhibition of apoptosis, induction of autophagy
Genetic Factors Influencing Infection Outcome	Host genetic variations affect susceptibility to infection and treatment response.	IL28B polymorphisms, HLA alleles

Immune Response to Hepatitis C Virus

The responses of the innate and adaptive immune systems to Hepatitis C virus (HCV) infection are complex and involve interactions between different HCV and host cell type specific effector populations. This response determines the outcome of infection directing whether the virus is quickly cleared or becomes chronic and persists [34, 36-38].

1. Innate Immune Response

- **Interferon Production:** IFNs, (IFN α and IFN β) produced by infected cells, are essential for the first antiviral response to HCV infection. These interferons induce signaling pathways that are themselves induced by ISGs with antiviral activity.
- **Natural Killer (NK) Cells:** Direct killing of infected cells by NK cells and production of the cytokine IFN-γ that enhances the antiviral state of surrounding cells is important for controlling HCV infection.
- **Dendritic Cells (DCs):** DCs are antigen presenting cells connecting innate and adaptive immunity. HCV can make them less able to function correctly and negatively impact their overall immune response.

2. Adaptive Immune Response

- **Humoral Immunity:** An essential part of the adaptive immune response against HCV are the production of neutralizing antibodies against HCV envelope proteins (E1 and E2). Nevertheless, because of high variability of these proteins, antibody mediated neutralization is often ineffective.

Cell-Mediated Immunity:

- **CD4+ T Cells:** Helping T cells, which are important for orchestrating an immune response, because they supply help to both B cells and CD8 T cells through cytokine production, are the helper T cells.
- **CD8+ T Cells:** Cytotoxic T lymphocytes (CTLs) target and kill HCV-infected cells. A robust CD8+ T cell response is associated with viral clearance, whereas an exhausted or dysfunctional CTL response often contributes to chronic infection.

3. Immune Evasion by HCV

- **Antigenic Variability:** HCV's genetic diversity, particularly in its envelope proteins, allows it to escape recognition by neutralizing antibodies.
- **Inhibition of Antigen Presentation:** HCV can interfere with the antigen presentation process, reducing the ability of infected cells to present viral antigens to CD8+ T cells.
- **Modulation of Immune Signaling:** The virus can modulate signaling pathways involved in immune activation, dampening the host's ability to mount an effective immune response.

Table 6 *(Immune Response to Hepatitis C Virus.)*

Immune Response Component	Description	Key Features/Processes
Innate Immune Response	The first line of defense against HCV infection, involving immediate but non-specific immune mechanisms.	- Type I interferons (IFN-α and IFN-β) production - Natural Killer (NK) cells - Dendritic Cells (DCs)
Adaptive Immune Response	Specific immune response that develops over time, involving both humoral and cell-mediated immunity.	- Neutralizing antibodies (humoral immunity) - CD4+ T helper cells - CD8+ cytotoxic T lymphocytes (CTLs)
Immune Evasion by HCV	Strategies employed by HCV to avoid detection and destruction by the host immune system.	- Antigenic variability - Inhibition of antigen presentation - Modulation of immune signaling

Table 7 *(Clinical Manifestations and Disease Progression of Hepatitis C Virus Infection.)*

Stage of Infection	Description	Clinical Features/Complications
Acute Hepatitis C	Initial phase following infection, which can be asymptomatic or symptomatic.	- Asymptomatic in many cases - Symptomatic phase: jaundice, fatigue, nausea, vomiting, abdominal pain
Chronic Hepatitis C	Persistent infection lasting more than six months, often asymptomatic.	- Mild non-specific symptoms (e.g., fatigue, depression) - Risk of liver damage increases over time

Liver Fibrosis and Cirrhosis	Progression from chronic infection leads to scarring of liver tissue.	- Fibrosis can progress to cirrhosis - Complications: liver failure, portal hypertension
Hepatocellular Carcinoma (HCC)	Increased risk of liver cancer in individuals with cirrhosis.	- Regular screening recommended for cirrhotic patients - Symptoms may include weight loss, abdominal pain, and jaundice
Extrahepatic Manifestations	Conditions affecting organs beyond the liver due to HCV infection.	- Mixed cryoglobulinemia - Renal disease - Dermatological conditions - Immune-mediated disorders (e.g., rheumatoid-like arthritis)

Challenges and Future Directions in Hepatitis C Virus Research and Treatment

Hepatitis C virus (HCV) infection is despite significant advances in understanding and treating HCV infection still. To improve patient outcomes and ultimately global eradication of HCV, addressing these challenges is critically important.

1. Viral Diversity and Resistance

- **Genetic Variability:** HCV is highly diverse within both its genotypes and subtypes. However, just because it is very variable makes developing a vaccine difficult and resistant of viral strain.
- **Emergence of Resistance:** Despite this, the advent of direct-acting antivirals (DAAs), have revolutionised the treatment of HCV but there is concern about the potential for viral resistance, especially in treatment experienced patients.

2. Access to Treatment

- **Healthcare Disparities:** There is great disparity in access to HCV testing and treatment between regions and populations. Barriers to care affect marginalized groups, including people with Substance Use Disorders, as well as those residing in low resource settings.
- **Cost of Treatment:** While the price of DAAs has become cheaper, this still makes these drugs too expensive in many countries, so that access to them for more people is not possible.

3. Long term outcomes post treatment

- **Reinfection Risk:** Although SVR in treated patients is possible, reinfection is still a risk, especially in high risk populations.
- **Post-Treatment Monitoring:** Long term follow up of individuals who have been treated for an infection is needed to see who develop complications such as liver cancer or hepatitis B reactivated.

4. Vaccine Development

- **Lack of Effective Vaccine:** There is no effective vaccine to cure HCV. The genetic variability of the virus poses enormous difficulties in development of the universally effective vaccine.
- **Research Directions:** Immune responses to HCV are being understood through ongoing research and potential vaccine candidates that elicit robust and lasting immunity are being identified.

5. Extrahepatic Manifestations

- **Systemic Impact of HCV:** Extrahepatic manifestations of HCV are researched in limited ways. Knowing these conditions enablesmore effective management of patients with these conditions.
- **Interdisciplinary Approaches:** Treatments for systemic effects of HCV require cooperative efforts of hepatologists, immunologists, and others for patient benefit.

CONCLUSION

Hepatitis C virus (HCV) remains a major global public health threat leading to millions of lives affected and consequent serious liver conditions. While direct acting antiviral treatments save lives, there remains a long way to go in order to tackle obstacles such as viral diversity, limited access to care and lack of a vaccine.

Addressing these challenges requires improvement in accessibility to testing and treatment, especially for underserved populations, and focuses on long term clinical outcomes and extrahepatic effects. Through our efforts to research the virus and promote equitable health care for those infected with HCV, we also can work to decrease the incidence of HCV and improve health outcome among the infected. Rigorous dedication to these initiatives will be crucial in fighting Hepatitis C.

REFERENCES

1. Irshad M, Gupta P, Irshad K. Molecular basis of hepatocellular carcinoma induced by hepatitis C virus infection. World J Hepatol. 2017;9(36):1305-14.
2. Vescovo T, Refolo G, Vitagliano G, Fimia GM, Piacentini M. Molecular mechanisms of hepatitis C virus–induced hepatocellular carcinoma. Clinical Microbiology and Infection. 2016;22(10):853-61.
3. Goto K, Roca Suarez AA, Wrensch F, Baumert TF, Lupberger J. Hepatitis C Virus and Hepatocellular Carcinoma: When the Host Loses Its Grip. Int J Mol Sci. 2020;21(9).
4. Dustin LB, Bartolini B, Capobianchi MR, Pistello M. Hepatitis C virus: life cycle in cells, infection and host response, and analysis of molecular markers influencing the outcome of infection and response to therapy. Clin Microbiol Infect. 2016;22(10):826-32.
5. Ashfaq UA, Javed T, Rehman S, Nawaz Z, Riazuddin S. An overview of HCV molecular biology, replication and immune responses. Virology Journal. 2011;8(1):161.
6. Lavie M, Goffard A, Dubuisson J. HCV glycoproteins: assembly of a functional E1–E2 heterodimer. Hepatitis C viruses: Genomes and molecular biology. 2006.

7. Tong Y, Lavillette D, Li Q, Zhong J. Role of Hepatitis C Virus Envelope Glycoprotein E1 in Virus Entry and Assembly. Front Immunol. 2018;9:1411.
8. Nguyen MH, Wong G, Gane E, Kao JH, Dusheiko G. Hepatitis B Virus: Advances in Prevention, Diagnosis, and Therapy. Clin Microbiol Rev. 2020;33(2).
9. Topi S, Gaxhja E, Charitos IA, Colella M, Santacroce L. Hepatitis C Virus: History and Current Knowledge. Gastroenterology Insights. 2024;15(3):676-707.
10. Shi ST, Lai MM. HCV 5′ and 3′ UTR: when translation meets replication. Hepatitis C Viruses: genomes and molecular biology. 2006.
11. Pan CQ, Zhang JX. Natural History and Clinical Consequences of Hepatitis B Virus Infection. Int J Med Sci. 2005;2(1):36-40.
12. Tabata K, Neufeldt CJ, Bartenschlager R. Hepatitis C Virus Replication. Cold Spring Harb Perspect Med. 2020;10(3).
13. Shi G, Suzuki T. Molecular Basis of Encapsidation of Hepatitis C Virus Genome. Frontiers in Microbiology. 2018;9.
14. Koch JO, Bartenschlager R. Modulation of hepatitis C virus NS5A hyperphosphorylation by nonstructural proteins NS3, NS4A, and NS4B. J Virol. 1999;73(9):7138-46.
15. Gawlik K, Gallay PA. HCV core protein and virus assembly: what we know without structures. Immunol Res. 2014;60(1):1-10.
16. Ng WC, Soto-Acosta R, Bradrick SS, Garcia-Blanco MA, Ooi EE. The 5' and 3' Untranslated Regions of the Flaviviral Genome. Viruses. 2017;9(6).
17. Nagy PD, Pogany J. The dependence of viral RNA replication on co-opted host factors. Nat Rev Microbiol. 2011;10(2):137-49.
18. Ploss A, Evans MJ. Hepatitis C virus host cell entry. Curr Opin Virol. 2012;2(1):14-9.
19. Zeisel MB, Barth H, Schuster C, Baumert TF. Hepatitis C virus entry: molecular mechanisms and targets for antiviral therapy. Front Biosci (Landmark Ed). 2009;14(9):3274-85.
20. Cohen S, Au S, Panté N. How viruses access the nucleus. Biochimica et Biophysica Acta (BBA) - Molecular Cell Research. 2011;1813(9):1634-45.
21. Rampersad S, Tennant P. Replication and Expression Strategies of Viruses: Viruses. 2018:55-82. doi: 10.1016/B978-0-12-811257-1.00003-6. Epub 2018 Mar 30.
22. Ferreira AR, Ramos B, Nunes A, Ribeiro D. Hepatitis C Virus: Evading the Intracellular Innate Immunity. J Clin Med. 2020;9(3).
23. Svitkin YV, Pause A, Lopez-Lastra M, Perreault S, Sonenberg N. Complete translation of the hepatitis C virus genome in vitro: membranes play a critical role in the maturation of all virus proteins except for NS3. J Virol. 2005;79(11):6868-81.
24. Miller S, Krijnse-Locker J. Modification of intracellular membrane structures for virus replication. Nat Rev Microbiol. 2008;6(5):363-74.
25. Romero-Brey I, Merz A, Chiramel A, Lee JY, Chlanda P, Haselman U, et al. Three-dimensional architecture and biogenesis of membrane structures associated with hepatitis C virus replication. PLoS Pathog. 2012;8(12):e1003056.
26. Ranjith-Kumar C, Kao CC. Biochemical activities of the HCV NS5B RNA-dependent RNA polymerase. Hepatitis C viruses: genomes and molecular biology. 2006.

27. Nomaguchi M, Ackermann M, Yon C, You S, Padmanabhan R. De novo synthesis of negative-strand RNA by Dengue virus RNA-dependent RNA polymerase in vitro: nucleotide, primer, and template parameters. J Virol. 2003;77(16):8831-42.
28. Herker E, Ott M. Unique ties between hepatitis C virus replication and intracellular lipids. Trends Endocrinol Metab. 2011;22(6):241-8.
29. Lindenbach BD. Virion assembly and release. Curr Top Microbiol Immunol. 2013;369:199-218.
30. Fiehn F, Beisel C, Binder M. Hepatitis C virus and hepatocellular carcinoma: carcinogenesis in the era of direct-acting antivirals. Current Opinion in Virology. 2024;67:101423.
31. Hoshida Y, Fuchs BC, Bardeesy N, Baumert TF, Chung RT. Pathogenesis and prevention of hepatitis C virus-induced hepatocellular carcinoma. J Hepatol. 2014;61(1 Suppl):S79-90.
32. Preciado MV, Valva P, Escobar-Gutierrez A, Rahal P, Ruiz-Tovar K, Yamasaki L, et al. Hepatitis C virus molecular evolution: transmission, disease progression and antiviral therapy. World J Gastroenterol. 2014;20(43):15992-6013.
33. Chigbu DI, Loonawat R, Sehgal M, Patel D, Jain P. Hepatitis C Virus Infection: Host¯Virus Interaction and Mechanisms of Viral Persistence. Cells. 2019;8(4).
34. Georgel P, Schuster C, Zeisel MB, Stoll-Keller F, Berg T, Bahram S, et al. Virus-host interactions in hepatitis C virus infection: implications for molecular pathogenesis and antiviral strategies. Trends Mol Med. 2010;16(6):277-86.
35. Quirino A, Marascio N, Branda F, Ciccozzi A, Romano C, Locci C, et al. Viral Hepatitis: Host Immune Interaction, Pathogenesis and New Therapeutic Strategies. Pathogens. 2024;13(9):766.
36. Sun J, Rajsbaum R, Yi M. Immune and non-immune responses to hepatitis C virus infection. World J Gastroenterol. 2015;21(38):10739-48.
37. Dustin LB. Innate and Adaptive Immune Responses in Chronic HCV Infection. Curr Drug Targets. 2017;18(7):826-43.
38. Obaid A, Naz A, Ikram A, Awan FM, Raza A, Ahmad J, et al. Model of the adaptive immune response system against HCV infection reveals potential immunomodulatory agents for combination therapy. Scientific Reports. 2018;8(1):8874.